Clinical trials: Rivaroxaban
Atrial Fibrillation, Stroke
Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study
The purpose of this study is to determine that a new drug called "Rivaroxaban®" is effective in preventing patients from forming clots after their heart rhythm has been reset by the cardiologist with an electrical device.
- Conditions
- Atrial Fibrillation, Stroke, Thrombo-embolism, Bleeding
- Trial name
- ARC (NCT01747746)
- Testing
- Rivaroxaban, Warfarin and Enoxaparin
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Cook County Health
Healthy Participants
Bioequivalence Study of Rivaroxaban 2.5 mg Tablets Under Fasting and Fed Conditions
This completed study compared how the body absorbed a single 2.5 mg dose of a test rivaroxaban tablet and the reference product (Xarelto) in healthy adults.
- Trial name
- NCT07807488
- Testing
- Rivaroxaban 2.5 mg Test Tablet, Rivaroxaban 2.5 mg Reference Tablet
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Qingdao University
Healthy
A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers
The purpose of this study is to assess the use of 2 different Prothrombin Complex Concentrates (PCCs) on their ability to reverse (normalize) the pharmacodynamic effects of rivaroxaban in healthy adult volunteers.
- Trial name
- NCT01656330
- Testing
- Rivaroxaban 20 mg twice daily, Rivaroxaban 20 mg once daily, Profilnine SD
- Where
- Belgium
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy
A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants
The purpose of this study is to assess the independent effects of both a 4-Factor prothrombin complex concentrate (PCC) - (Kcentra) and Tranexamic acid (TXA) on the bleeding parameters (bleeding duration and blood volume)…
- Trial name
- NCT02561923
- Testing
- Rivaroxaban, Tranexamic acid, Kcentra, a 4-factor PCC
- Where
- United States
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Janssen Scientific Affairs, LLC
Bioequivalence
Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 10 mg in Healthy Male Volunteers in Fasting Conditions
This is an open-labeled, laboratory-blinded, randomized, two period, single-center, crossover, comparative study, where each participant will be randomly assigned to the reference (Xarelto®, 10 mg film-coated tablets) or the test…
- Trial name
- NCT04753489
- Testing
- Rivaroxaban film-coated tablet 10 mg, Xarelto® film-coated tablet 10 mg
- Where
- Russia
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Pharmtechnology LLC
Healthy Volunteers
Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants
This study is researching experimental drugs called REGN9933 and REGN7508 (called "study drugs") and comparing their effects to approved treatments of rivaroxaban and aspirin (called "standard treatments").
- Trial name
- NCT06444178
- Testing
- Aspirin, REGN9933, REGN7508
- Where
- United Kingdom
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Deep Venous Thrombosis, Colonic Cancer
Chemoprophylaxis With Rivaroxaban for Lower Limb Deep Vein Thrombosis in Colorectal Cancer
The chemoprophylaxis of deep vein thrombosis (DVT) with subcutaneous low-molecular-weight heparin (enoxaparin) in the postoperative period of elective surgeries is already well established in the literature and in clinical…
- Trial name
- Ésquilo (NCT05303818)
- Testing
- Rivaroxaban 10 MG
- Where
- Brazil
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Hospital do Servidor Publico Estadual
Healthy
Bioequivalence Study of Rivaroxaban 10 mg Film-coated Tablets
This study was an open-label, randomized, single-dose, two-period, two-sequence, two-way crossover study under fasting conditions which included 28 healthy adult male and female subjects.
- Trial name
- NCT06558058
- Testing
- Rivaroxaban 10 mg film-coated tablet, Xarelto 10 mg film-coated tablet
- Where
- Indonesia
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Dexa Medica Group
Therapeutic Equivalency
Bioequivalence Study in Healthy Subjects, 2*5 mg Tablets Rivaroxaban Versus 1*10 mg Tablet Rivaroxaban
The drug investigated in this study is Rivaroxaban, a novel, once-daily, oral anticoagulant for the prevention (prophylaxis) of deep vein thrombosis (DVT) which may lead to a pulmonary embolism (PE) in people undergoing knee or…
- Trial name
- NCT01436526
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy
Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT
This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and safety of ciraparantag administered to healthy volunteers anticoagulated with rivaroxaban measuring clotting times using Whole Blood…
- Trial name
- NCT03172910
- Testing
- Ciraparantag, Rivaroxaban
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Healthy Volunteer
Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants
The primary objective of the study is to determine whether aspirin alone or aspirin combined with various doses of rivaroxaban causes subclinical GI blood loss as determined by the HemoQuant assay.
- Trial name
- NCT05546957
- Testing
- Aspirin, rivaroxaban low dose, rivaroxaban high dose
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Healthy Volunteer
BE Study of Two Formulations of Rivaroxaban 2.5 mg in Healthy Subjects
The objective of this study was to compare the pharmacokinetic profiles and bioequivalence of rivaroxaban after a single oral dose of rivaroxaban 2.5 mg tablet in healthy Korean subjects.
- Trial name
- NCT05418803
- Testing
- YHP1807 Tab. 2.5mg, YHR1901 Tab. 2.5mg
- Where
- South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Healthy
Bioequivalence Study of Rivaroxaban 20 mg Film-coated Tablets
This study was an open-label, randomized, single-dose, two-period, two-sequence, two-way crossover study under fed conditions which included 28 healthy adult male and female subjects.
- Trial name
- NCT06558045
- Testing
- Rivaroxaban 20 mg film-coated tablet, Xarelto 20 mg film-coated tablet
- Where
- Indonesia
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Dexa Medica Group
Healthy, Renal Insufficiency
A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function
The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamics of rivaroxaban when administered with erythromycin to study participants with mild or moderate renal impairment compared to the pharmacokinetics…
- Trial name
- NCT01309438
- Testing
- Rivaroxaban (normal renal function), Rivaroxaban (mild and moderate renal impairment), Erythromycin (normal renal function)
- Where
- 4 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Atrial Fibrillation, Acute Coronary Syndrome
Antithrombotic Triple Therapy in Humans
Background:The acute coronary syndrome (ACS) is a complication of coronary artery disease (CAD) and associated with increased mortality.
- Trial name
- NCT01812200
- Testing
- Dabigatran, Ticagrelor, ASA, Rivaroxaban, Ticagrelor, ASA, Phenprocoumon, Ticagrelor, ASA
- Where
- Austria
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Novel Oral Anticoagulants, NOACs
Impact of Biomarkers on Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants
It is general that there are many factors for individual differences of drugs in clinical application, of which genetic factors accounted for more than 20%.
- Conditions
- Novel Oral Anticoagulants, NOACs, Rivaroxaban, Apixaban
- Trial name
- NCT03161496
- Testing
- detection of genotype
- Where
- 17 sites in China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Cui Yimin
Atrial Fibrillation
The Effectiveness of Patch-Based Screening for Pre-Symptomatic Atrial Fibrillation to Improve Patient Outcome
The goal of the screening trial is to determine whether early screening for atrial fibrillation improves outcomes, including lowering the chance of death, hospitalization for stroke, blood clots, heart failure, heart attack, and…
- Trial name
- VALIANT-AF-S (NCT06953778)
- Testing
- Zio XT® Patch
- Where
- United States
- Volunteers
- 24,060 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Bioequivalence
Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 20 mg in Healthy Male Volunteers Under Fed Conditions
This is an open-labeled, laboratory-blinded, randomized, two period, single-center, crossover, comparative study, where each participant will be randomly assigned to the reference (Xarelto®, 20 mg film-coated tablets) or the test…
- Trial name
- NCT04729998
- Testing
- Rivaroxaban film-coated tablet 20 mg, Xarelto® film-coated tablet 20 mg
- Where
- Russia
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Pharmtechnology LLC
Morbid Obesity, Bariatric Surgery Candidate
Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery
Rivaroxaban versus enoxaparin for prophylaxis of venous thromboembolism in morbidly obese patients undergoing bariatric surgery: An open_label randomized controlled trial
- Trial name
- NCT06689241
- Testing
- Enoxaparin, rivaroxaban
- Where
- Egypt
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Alexandria University
End-Stage Renal Disease
A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis
The purpose of this study is to assess the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) and pharmacodynamics (the way a drug may change body function) of a single 15-milligram…
- Trial name
- NCT02289703
- Testing
- Rivaroxaban 15 mg
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC